Prithviraj Bose, MD, of MD Anderson Cancer Center discusses treatment options for patients progressing with myelofibrosis.
Prithviraj Bose, MD, of MD Anderson Cancer Center discusses treatment options for patients progressing with myelofibrosis.
How do you treat progression in myelofibrosis?
So, it’s a lot of things, and currently there is not a whole lot that is available for these patients. Ruxolitinib is our standard first-line drug for most patients with myelofibrosis and progression to me generally mean progression on ruxolitinib. So, we just had the FDA approve fedratinib, so that is a new option now, which certainly would be a valid option in a good number of patients who progress on ruxolitinib. There is data from the JAKARTA-2 study supporting fedratinib’s use in the post-ruxolitinib setting.
But where it gets interesting is that you have to look at the definitions used in various trials that have studied agents in the post-ruxolitinib setting. So, JAKARTA-2, for example, originally had a fairly loose definition and then the data were reanalyzed using a stringent definition, which I hope is becoming more of a consensus because the recent trial of pacritinib, PAC203—pacritinib is another JAK 2 inhibitor—used the same definitions as they used in the revised analysis of JAKARTA-2. So, hopefully some sort of a consensus is emerging in the field.
And what was interesting was when they used the revised definition, the response rates dramatically changed. They originally reported spleen response rate was 55% and with the new definition it was 30%. Symptom response rate was virtually identical, 26% and 27% on the original and the reanalysis.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More